What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...

Torex Gold Resources Inc. (TSE:TXG – Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$28.99 and ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

The put/call ratio of TXG is 0.87, indicating a bullish outlook. What are Other Shareholders Doing? ARK Investment Management holds 11,944K shares representing 11.16% ownership of the company.

ALAN MATEO, a director at $TXG, bought 40,000 shares of the company on 02-21-2025 for an estimated $445,572. This trade was reported by Quiver Quantitative using data ...